Trial reportDiabetes2013
Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes.
Trial report in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 121 citations in OpenAlex.
- G-CSF and Exenatide Might Be Associated with Increased Long-Term Survival of Allogeneic Pancreatic Islet Grafts.PloS one · 2016 · on this mapTrial
- Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.Diabetes care · 2015Trial
- Impact of preformed donor-specific anti-HLA antibodies on pancreatic islet transplantation outcomes: do they matter as they do in solid organ transplantation?Frontiers in immunology · 2026Review
- Nanotechnology-Driven Precision Modulation of Transplant Immunity: From Mechanistic Insights to Clinical Tolerance.International journal of nanomedicine · 2026Review
- Stem cell therapy: a paradigm shift in reversing type 1 diabetes mellitus.Annals of medicine and surgery (2012) · 2025Review
- Induction of immune education in type 1 diabetes through controlled allogeneic islet rejection at onset: a monocentric open-label pilot study.EClinicalMedicine · 2025Article
- Mouse Models and Experimental Protocols to Study Alloantibody-Mediated Transplant Rejection.Current protocols · 2025Article
- Article
- Germinal Center B Cells are Uniquely Targeted by Antibody-Suppressor CXCR5Transplantation direct · 2025Article
- Blockade of CD155 and CD276 by Monoclonal Antibodies Fosters Immune Tolerance and Promotes Stable Engraftment of iPSC-Derived Islets in Allogeneic Humanized Mice.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs.Frontiers in immunology · 2025Article
- Advances and challenges of the cell-based therapies among diabetic patients.Journal of translational medicine · 2024Review
- Innovations in bio-engineering and cell-based approaches to address immunological challenges in islet transplantation.Frontiers in immunology · 2024Review
- Applications of Genome-Editing Technologies for Type 1 Diabetes.International journal of molecular sciences · 2023Review
- Delayed graft rejection in autoimmune islet transplantation via biomaterial immunotherapy.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2023Article
- Review
- Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge.Frontiers in immunology · 2023Review
- Impact of GAD65 and IA2 autoantibodies on islet allograft survival.Frontiers in clinical diabetes and healthcare · 2023Article
- A unique profile of insulin antibody titer in islet-transplanted patients.Journal of diabetes investigation · 2022Article
- The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.Scientific reports · 2022Observational
Corrections and comments
- Commented on by
Authors and funding
17 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term clinical outcome of islet transplantation is hampered by the rejection and recurrence of autoimmunity. Accurate monitoring may allow for early detection and treatment of these potentially compromising immune events. Islet transplant outcome was analyzed in 59 consecutive pancreatic islet recipients in whom baseline and de novo posttransplant autoantibodies (GAD antibody, insulinoma-associated protein 2 antigen, zinc transporter type 8 antigen) and donor-specific alloantibodies (DSA) were quantified. Thirty-nine recipients (66%) showed DSA or autoantibody increases (de novo expression or titer increase) after islet transplantation. Recipients who had a posttransplant antibody increase showed similar initial performance but significantly lower graft survival than patients without an increase (islet autoantibodies P < 0.001, DSA P < 0.001). Posttransplant DSA or autoantibody increases were associated with HLA-DR mismatches (P = 0.008), induction with antithymocyte globulin (P = 0.0001), and pretransplant panel reactive alloantibody >15% in either class I or class II (P = 0.024) as independent risk factors and with rapamycin as protective (P = 0.006) against antibody increases. DSA or autoantibody increases after islet transplantation are important prognostic markers, and their identification could potentially lead to improved islet cell transplant outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.